Early T-Cell Chimerism Is Valuable in Predicting Early Mortality from Steroid-Resistant Acute Graft Versus Host Disease after Myeloablative Allogeneic Haematopoietic Cell Transplantation  by Minculescu, Lia et al.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S257eS285S274aGVHD, it was 6.5 infections/1000 person-days (p-val-
ue¼0.022). These data support the hypothesis that gut
aGVHD predisposes patients to development of EB-BSI, given
the asymmetric distribution of EB-BSI after onset of aGVHD.
We plan to analyze the infection densities in several other
groups and risk factors associated with higher infection
density in patients with gut aGVHD speciﬁcally.
To our knowledge, this is the ﬁrst study to demonstrate that
the development of gut aGVHD increases the risk for EB-BSI.
Strategies to reduce the elevated risk of EB-BSI in patients
who develop gut aGVHD, such as prophylactic use of pro-
biotics, should be considered based on these ﬁndings.425
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Graft-verses-host disease (GVHD) is a major complication in
allogeneic bone marrow transplantation (allo-HSCT), and
characterized by epithelial cell injury in skin, intestine and
liver. The development of GVHD involves donor T cell acti-
vation including proliferation, differentiation and inﬂam-
matory cytokine production, which lead to speciﬁc tissue
damage. The interactions between the complement system
and lymphocytes have been shown to regulate alloreactive T
cell and APC function in the setting of allograft rejection.
There are three pathways that activate the complement
system: the alternative, lectin and classical pathways; all of
which converge on the formation of the C3 convertase to
propagate the complement cascade. Recently, we reported
that mice deﬁcient in the central component of complement
system C3 had signiﬁcantly lower GVHD-related mortality/
morbidity and C3modulated Th1/Th17 polarization inmouse
GVHD. Given the emerging role of complement in alloim-
mune responses and T cell activation in animal models, it
is important to address whether C3 modulates human
T cell activation, polarization, expansion and differentiation.
Compstatin is a 13-residue cyclic peptide that speciﬁcally
binds to human C3 and inhibits complement activation, thus
a favorable precursor peptide for the development of an anti-
complement drug for oral use. Herein, we investigate the
functional consequences of blocking C3 activation on human
T cell activation. The production of IFN-g (Th1), IL-4 (Th2), IL-
17 (Th17), IL-2 and TNF-awas determined simultaneously in
normal donor samples to examine whether Compstatin af-
fects T cell activation and polarization in vitro. We found that
blocking C3 activation with Compstatin signiﬁcantly inhibits
Th1/Th17 polarization in activated human CD4+ T cells. The
production of IL-2 and TNF-a are reduced in CD4+ but not in
CD8+ T cells. Moreover, Compstatin treatment signiﬁcantly
decreases the proliferation of both CD4+ and CD8 +T cells
stimulated with OKT3 plus CD28 or allogeneic DCs in MLR. It
has been reported that patients with sclerotic-type chronic
GVHD (ScGVHD) have signiﬁcantly elevated C3 in the serum.
We examined the degree of C3 deposition in the skin and lip
samples retrieved from our GVHD tissue repository of
human allo-HSCT recipients. In the skin GVHD tissues, C3depositions are found in the squamous epithelium and
dermis, blood vessels and damaged sweat glands. In the lip
biopsy of GVHD patients, C3 depositions are found in the
lesions associated with gland damage and regeneration, and
damaged blood vessels. In summary, we conclude that C3
mediates Th1/Th17 polarization in human T cell activation
and skin GVHD in patients. Studies on complement system
and GVHD will not only signiﬁcantly advance our knowledge
of GVHD but also provide a rationale for using complement
inhibitors as novel therapeutic interventions for GVHD.426
Early T-Cell Chimerism Is Valuable in Predicting Early
Mortality from Steroid-Resistant Acute Graft Versus Host
Disease after Myeloablative Allogeneic Haematopoietic
Cell Transplantation
Lia Minculescu 1, Hans Ole Madsen 2, Henrik Sengelov 3.
1 Clinical Immunology, National University Hospital,
Copenhagen, Denmark; 2 Clinical Immunology, National
University Hospital, Copemhagen, Denmark; 3 Department of
Hematology L, National University Hospital, Rigshospitalet,
Copenhagen, Denmark
The aim of this study was to evaluate the impact of early
chimerism status on incidence and clinical course of acute
GVHD in allogeneic transplant recipients. From March 2008
to February 2013, 106 eligible patients were included in the
study. Median patient agewas 40 (16-58) years with 66 (62%)
males and 40 (38%) females. Pre-transplant diagnoses were
AML (44 patients, 42%), ALL (29 patients, 27%), MDS (17 pa-
tients, 16%), CML (8 patients, 8%), NHL (2 patients, 2%) and
other (6 patients, 6%). Donors were HLA-identical siblings in
33 (31%) patients and matched unrelated donors in 73 (69%)
patients. Stem cell sources were bone marrow (61 patients,
58%) and peripheral blood (45 patients, 42 %). Patients were
conditioned with Cyclophosphamide and TBI 12 Gy (63 pa-
tients, 59%), VP16 and TBI 12 Gy (31 patients, 29%), Cyclo-
phosphamide and Busulfan (10 patients, 9%), moreover 1
patients received Busulfan and Melphalan and another pa-
tient Busulfan and VP16.
T-cell line speciﬁc chimerismwas analysed by PCR-VNTR and
chimerism samples were measured on day 35. Donor
chimerism (DC) was deﬁned as 95% or more cells of donor
origin within CD4 and CD8 T-cells and mixed chimerism
(MC) as less than 95% donor CD4 and CD8 T-cells. At a follow-
up time of 767 (140-1940) days 71 (67%) patients were still
alive. Among deceased patients, cause of death was TRM in
23 (66%) patients and relapse in 12 (34%) patients. Acute
GVHD occurred in 68 (64%) patients with 49 (46%) patients
diagnosed with grade II-IV aGVHD. The incidence and grade
of aGVHD was not different in DC versus MC patients. Early
survival probability at day 180 estimated by Kaplan-Meier
showed signiﬁcantly better outcome for patients with MC
compared to DC (p¼0.04). Death from TRM with relapse
as competing risk analysed with cumulative incidence
emphasized poorer outcome forMC patients compared to DC
patients (p¼0.03).We then analysed the clinical course in MC
and DC patients diagnosed with aGVHD grade II-IV who later
on died from TRM. Of these 21 patients, 12/14 DC patients
compared to 1/7 MC were under treatment with either high
dose Prednisolone ( 1.5 mg/kg body weight) or Inﬂiximab
by their time of death (p¼0.007, ﬁgure 1), associating early T-
cell DC with steroid-resistant aGVHD. This suggest, that even
though the incidence and grade of aGVHD were not different
between patients with DC versus MC, the clinical course of
aGVHD seem to differ signiﬁcantly in the two groups with
higher mortality from steroid-resistant aGVHD in DC
Fig 1. Patients with grade II-IV acute GVHD, DC: Donor T-cell Chimerism, MC:
Mixed T-cell Chimerism. Diagonal pattern in bar indicates patients progressing
to steroid resistant (SR) GVHD. P¼0.007.
Table 1
Workup panel results of suspected Myositis.* 10 excluded due to lack of
testing from n¼68.
No. of
patients
Muscle Biopsy Enzymes+ Antibodies+ EMG+ MRI/PET+
7 Positive 6/7 4/7 7/7 2/2
2 Equivocal 2/2 0/2 1/1 1/1
5 Negative 1/5 0/3 4/4 0/3
44 Not Done 30/40 7/23 8/16 11/19
58* TOTAL 39/54 11/35 20/28 14/25
Fig-1. Number of patients meeting Myositis criteria.
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early predictor of development of steroid-resistant GVHD.
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Background: There is paucity of data on diagnostic criteria of
Myositis/Muscle chronic Graft-versus-Host disease [cGVHD]
due to rarity of the condition (<0.7% of all Allogeneic-
Hematopoietic-Stem-Cell-Transplants [HSCT]. Myalgias are
common after HSCT and confounding factors such as drugs
(statins, steroids etc.), infections (muscle abscess) and tumor
inﬁltration make diagnosis elusive. A diagnostic algorithm is
lacking.
Methods: We retrospectively analyzed all allogeneic-HSCTs
through the Mayo Clinic Database from Jan 1994-July 2013 to
search for cases of myositis in association with cGVHD using
terms “GVH”, “Muscle biopsy” and “Myositis”. Diagnostic
criteria utilized were 1) Muscle Biopsy; 2) Elevated Enzymes:
CK or Aldolase; 3) Serum Antibodies: ANA, anti-striated-
muscle, Anti Ro/Jo/La, Sm, Scl-70, RNP 4) EMG and 5) Imag-
ing: MRI or PET scan.
Results: Of 1058 screened allogeneic-HSCT, 68 were sus-
pected clinically of having myositis, mostly presenting as
focal or diffuse myalgias. 14 had muscle biopsies. 7 had
conﬁrmedmyositis (Age 43-66 yrs., median 47). Median time
to diagnosis was 19 months post-HSCT. All had cGVHD
involving at least one other organ. 5/7 had AML and 6/7
received a ﬂudarabine based conditioning. All biopsy positive
and 2 biopsy indeterminate patients met at least 2 additional
criteria besides biopsy (total criteria met 3). Of the 61 pa-
tients that were biopsy negative or not biopsied, none met 3
criteria (except 2 who could not be biopsied). 17 were tested
but met none of the criteria (excluded). Remaining met 2
criteria not deemed sufﬁcient for diagnosis. All biopsy
proven patients received prednisone treatment. 5 received
additional therapies including IVIG, ECP, Rituximab and
Sirolimus.
Conclusions: Muscle biopsy, while conﬁrmative, is invasive
and is rarely pursued (20%). Only half of the biopsies were
positive for myositis, likely due to patchy nature of theConﬂicts of Interest: Nonedisease. All biopsy proven myositis patients met 3 criteria.
Myositis as a component of cGVHD can be diagnosed using a
composite of autoantibodies, muscle enzymes, EMG and
imaging. This new criteria could be used to establish an al-
gorithm in delineating the need for muscle biopsy for sus-
pected myositis. (Fig 1 & Table 1).428
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